Tesamorelin Explained: What It Is, What It's Approved For, and What the Research Shows

The short answer: tesamorelin is a lab-made version of the hormone that tells your pituitary gland to release growth hormone. It's an FDA-approved prescription drug, sold as Egrifta, for one use only: reducing excess belly fat in adults with HIV who have a fat-redistribution condition called lipodystrophy.

Everything else you'll read about it, from belly fat in people without HIV to fatty liver to "anti-aging" after 50, is research, not an approved use. Some of that research is solid and some of it is thin. This post sorts out which is which, using the drug label and the published trials.

Status as of October 24, 2026: tesamorelin is FDA-approved only as Egrifta WR and Egrifta SV, for excess abdominal fat in adults with HIV and lipodystrophy. It isn't approved for weight loss or any other use. This post describes what the label and the trials say. It isn't medical advice. Ask your doctor whether any of it applies to you.

Updated October 2026. Label, prices and FDA lists re-checked on October 24, 2026.

Want the short version of what's actually approved, legal and tested? Get the free BHN cheat sheet.

Tesamorelin is a copy of growth hormone-releasing hormone (GHRH), the signal your brain sends to the pituitary to release growth hormone. It doesn't contain growth hormone. It prompts your body to release its own.

The label describes it as the full 44-amino-acid sequence of human GHRH with a small chemical tail added to one end. In lab tests it activates the GHRH receptor "with similar potency" to the natural hormone. That triggers the "pulsatile release of endogenous growth hormone," which the label calls "both anabolic and lipolytic," meaning it builds tissue and breaks down fat. Growth hormone then raises IGF-1, a growth factor made mostly in the liver (Egrifta WR label).

It doesn't last long in the blood. The label puts its half-life at about 11 minutes. That matters later, when we compare it with CJC-1295.

Where it sits among the other growth hormone peptides is covered in your GH stack, explained honestly.

One thing. The label says Egrifta WR "is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy" (Egrifta WR label).

The same label lists what it is not for. It "is not indicated for weight loss management as it has a weight neutral effect." And "long-term cardiovascular safety" hasn't been established.

Sources: Egrifta WR label, rev. 03/2025, Egrifta SV label on DailyMed, Theratechnologies, March 25, 2025.

Theratechnologies says the WR version "is set to replace" Egrifta SV.

In the approval trials, it reduced visceral fat, the fat packed around the organs, by roughly 14% to 18% in six months in adults with HIV. Body weight didn't change, and the fat came back when people stopped.

Here's what the label's two main trials measured.

Both trials enrolled adults aged 18 to 65 with HIV, lipodystrophy and a large waist. The average age was 48 and about 85% were men. People took tesamorelin or a placebo daily for 26 weeks, and visceral fat was measured by CT scan (Egrifta WR label).

That last point is the one most "belly fat peptide" posts skip. The effect lasted only as long as the drug did.

Without HIV, the data is one small trial. Researchers at Massachusetts General Hospital gave tesamorelin or placebo for 12 months to 60 adults with abdominal obesity and lower-than-normal growth hormone output. Visceral fat fell 16 cm² on tesamorelin and rose 19 cm² on placebo, with no change in blood sugar measures (Makimura et al., JCEM, 2012). The trial took people aged 18 to 55. Women had to have hormone levels typical of before menopause and could not be on hormone therapy (ClinicalTrials.gov NCT00675506).

That one trial hasn't turned into an approval. Cigna's current coverage policy lists "abdominal obesity in a patient without HIV" as not covered because "more data are needed" (Cigna, effective Aug 1, 2026).

If you've seen tesamorelin paired with a GLP-1, that's a different conversation: why Reta + Tesa isn't a "fat loss stack".

Two trials in people with HIV found less liver fat on tesamorelin than placebo. A trial in people without HIV has posted results but, as far as I can find, no published paper yet. It isn't approved for any liver condition.

Small trials, mostly in one population, from one research group. Promising is a fair word. Proven isn't.

Not much. The approval trials stopped at age 65, and the label says "there is no information" on use in people over 65. No trial has studied tesamorelin in menopausal women as a group.

Here's what does exist.

The approval trials. Ages 18 to 65, average age 48, about 85% men, all with HIV (Egrifta WR label). Women made up only about 15% of the people in them.

One trial in older adults without HIV. A University of Washington trial gave tesamorelin or placebo for 20 weeks to 152 adults aged 55 to 87, average age 68. 89 were women, and estrogen therapy was allowed. Its main question was memory and thinking, and it reported a favorable effect, mostly on tests of executive function. On body composition, body fat fell 7.4% and lean mass rose 3.7%, with similar changes in men and women (Baker et al., Arch Neurol, 2012).

Two details from that paper matter for this age group. Side effects were reported by 68% on tesamorelin vs 36% on placebo, and more often by women. Doses were cut back because of side effects in 11 women and 2 men. Fasting insulin rose 35% in the group with mild memory problems (full text, PMC).

Menopause. I searched PubMed for tesamorelin trials in menopausal or postmenopausal women on October 24, 2026 and found none. The one non-HIV belly-fat trial effectively left postmenopausal women out. If menopause is why you're asking, that gap is the honest answer, and it's a question for your doctor.

Per the label, the most common are joint pain, injection-site redness and itching, pain in the arms or legs, swelling, and muscle aches. The more serious warnings involve blood sugar, IGF-1 and cancer risk.

Source: Egrifta WR label, sections 5 and 6. Trials were in adults with HIV.

The warnings worth knowing:

Yes, as a prescription drug. Egrifta is legal with a prescription. The trouble is the gray area around it: compounded copies and "research use only" vials.

Compounded tesamorelin. Because tesamorelin is a chain of more than 40 amino acids, federal rules classify it as a protein (21 CFR 600.3), and Egrifta is licensed as a biologic (DailyMed lists it under BLA 022505). FDA's guidance says biologics "are not eligible for the exemptions for compounded drugs" that let pharmacies compound (FDA guidance, 2018). The compounding industry's own trade group agrees: it wrote that the 2020 switch to biologic status "made both tesamorelin and human chorionic gonadotropin (HCG) ... ineligible for compounding" (Alliance for Pharmacy Compounding, 2024). So a "compounded tesamorelin" listing isn't on a legal compounding path, whatever the price.

Research-use-only vials. Tesamorelin is also sold online as a "research peptide." In an August 24, 2026 warning letter, FDA listed a seller's "Tesamorelin Research Peptide" among "unapproved new drugs" and said the website showed the products were "intended to be drugs for human use" despite the lab-use labeling (FDA warning letter, Aug 24, 2026). What separates a research vial from the approved drug is covered in research grade vs pharmaceutical grade.

Sport. Tesamorelin is on the World Anti-Doping Agency's 2026 prohibited list by name, under growth hormone releasing factors (2026 Prohibited List, official Dutch publication). If you're tested, it's banned.

Without insurance, about $11,000 for a 28-day box of Egrifta WR. With insurance, it usually needs prior approval, and plans typically approve it only for the labeled HIV use.

Cash price. Drugs.com lists Egrifta WR at "around $11,030 for a supply of 1 kit" on October 24, 2026 (Drugs.com). Per the label, one box holds four vials, and each mixed vial covers seven days, so a box is 28 days.

With insurance. Two current policies show the pattern:

Help from the maker. Theratechnologies runs a co-pay program for "qualifying patients" with commercial insurance and a patient assistance program that "offers qualifying patients THERA medications at no cost." It doesn't publish a dollar figure for either (THERA patient support).

Compounding pharmacy prices. You'll find them quoted online, but as covered above, there's no legal compounding route for tesamorelin. I'm not printing a price for a channel that isn't supposed to exist.

Both are man-made versions of GHRH. The big differences are how long they last and what's behind them. Tesamorelin is an approved drug with phase 3 trials. CJC-1295 has never been approved for anything.

Sources: Egrifta WR label, Teichman et al., JCEM, 2006, FDA compounding safety page, Apr 22, 2026, FDA 503A nominations list, May 14, 2026, 2026 Prohibited List.

In the CJC-1295 study, one injection raised growth hormone 2 to 10 times for six days or more and IGF-1 1.5 to 3 times for 9 to 11 days. The authors reported no serious adverse reactions in that study. FDA's later review, done when CJC-1295 was nominated for compounding, flagged heart-rate effects and said "available clinical data are limited." The nomination was withdrawn, and CJC-1295 isn't in any category of FDA's current compounding nominations list. The full list history is on the compounding status tracker.

So "tesamorelin vs CJC-1295" isn't two versions of the same thing. One has a label, a trial record and a known side-effect profile in one population. The other has a few weeks of hormone measurements in healthy volunteers.

In the people it's approved for, it reliably shrinks the fat around the organs while it's being taken, without changing body weight, and the fat returns when it's stopped. Outside that group, there's one small belly-fat trial, a few liver-fat trials mostly in HIV, and one 20-week trial in older adults. That's a real start. It isn't the "belly fat peptide for over 50" story you'll see sold.

If you're weighing it, the label's warnings on blood sugar, IGF-1 and cancer history are the place to start with your doctor. A baseline panel helps with that conversation, and the minimum bloodwork stack lays one out.

For research-grade context only, here's how I pick a peptide vendor.

The vendor links on that page are affiliate links. If you buy through them, BHN earns a commission.

Want the one-page version of what's approved, what's legal and what's actually been tested? Get the free BHN cheat sheet.